Analysts Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) PT at $13.75

Voyager Therapeutics, Inc. (NASDAQ:VYGR) has been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $13.75.

Several research analysts recently issued reports on VYGR shares. Wedbush reissued an “outperform” rating and issued a $8.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Voyager Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, HC Wainwright lowered their price target on shares of Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday, November 12th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Wexford Capital LP bought a new position in shares of Voyager Therapeutics in the 3rd quarter worth $42,000. Bank of Montreal Can bought a new stake in shares of Voyager Therapeutics in the 2nd quarter valued at about $36,000. Coldstream Capital Management Inc. purchased a new position in shares of Voyager Therapeutics in the 3rd quarter worth approximately $55,000. EHP Funds Inc. bought a new position in shares of Voyager Therapeutics during the 3rd quarter worth approximately $58,000. Finally, R Squared Ltd purchased a new stake in Voyager Therapeutics during the second quarter valued at approximately $48,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Voyager Therapeutics Trading Down 2.4%

Shares of VYGR opened at $4.00 on Wednesday. The firm has a fifty day moving average price of $4.09 and a 200-day moving average price of $4.03. The firm has a market capitalization of $222.40 million, a P/E ratio of -1.85 and a beta of 1.28. Voyager Therapeutics has a 12-month low of $2.64 and a 12-month high of $5.96.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.06. The company had revenue of $11.15 million during the quarter, compared to analyst estimates of $7.86 million. Voyager Therapeutics had a negative net margin of 404.85% and a negative return on equity of 48.94%. Analysts predict that Voyager Therapeutics will post -0.91 earnings per share for the current year.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.